Postmenopausal Osteoporosis Market size was over USD 10.31 billion in 2024 and is anticipated to cross USD 20.43 billion by 2037, witnessing more than 5.4% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of postmenopausal osteoporosis is estimated at USD 10.76 billion. In recent years, the remarkable progress in monoclonal antibody therapy has emerged as a pivotal growth driver in the postmenopausal osteoporosis treatment market. A study, involving over 7,800 women, revealed a significant 68% reduction in the relative risk of vertebral fractures compared to a placebo group.
In addition, as denosumab and other monoclonal antibodies continue to shape the landscape of postmenopausal osteoporosis treatment, the postmenopausal osteoporosis market is poised for substantial growth, driven by the increasing acceptance of these innovative therapies among healthcare professionals and patients alike. The emphasis on targeted, biologically-driven interventions underscores a paradigm shift in the approach to managing postmenopausal osteoporosis, fostering optimism for improved patient outcomes and a burgeoning market.
Growth Drivers
Challenges
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
5.4% |
|
Base Year Market Size (2024) |
USD 10.31 billion |
|
Forecast Year Market Size (2037) |
USD 20.43 billion |
|
Regional Scope |
|
Type (Pharmacological Therapies, Non-Pharmacological Interventions)
The pharmacological therapies segment in the postmenopausal osteoporosis market is estimated to gain the largest revenue share of about 60% in the year 2037. The segment growth can be set to the evolving treatment paradigms and improved safety profiles. A landmark clinical trial demonstrated that raloxifene, a widely used SERM, significantly reduced the risk of vertebral fractures by 30-50% in postmenopausal women. The study also highlighted the positive impact of SERMs on bone mineral density.
As treatment paradigms evolve towards personalized medicine, the safety profiles of SERMs make them a favorable choice for women with specific health considerations, such as a history of breast cancer. The balance of efficacy and safety positions SERMs as a key growth driver in the pharmacological armamentarium against postmenopausal osteoporosis. Monoclonal antibodies, particularly denosumab, have gained momentum in the postmenopausal osteoporosis market propelled by their enhanced efficacy and targeted action mechanisms.
End User (Hospitals, Clinics, Home Healthcare)
Based on end user, hospitals segment is expected to hold largest revenue share of about 45% from 2024 to 2037. For the hospital segment, the rising number of fractures linked to osteoporosis is a major growth driver for postmenopausal osteoporosis market in this segment. A large proportion of fractures, especially hip fractures in the senior population, are caused by osteoporosis, according to a study published in the Journal of the American Geriatrics Society. The study reported that over 300,000 hip fractures occur annually in the United States, leading to hospitalizations.
As fractures often necessitate immediate medical attention and specialized care, hospitals experience a surge in demand for their services. The rising number of osteoporosis-related fractures reinforces the importance of hospitals as key providers of comprehensive care, driving growth in this segment. The growth of hospitals in the market expansion is influenced by the increasing number of surgical interventions for osteoporotic fractures.
Our in-depth analysis of the global postmenopausal osteoporosis market includes the following segments:
|
Type |
|
|
End User |
|
|
Risk Factors |
|
|
Comorbid Conditions |
|
APAC Market Statistics
Postmenopausal osteoporosis market in the Asia Pacific region, amongst the market in all the other regions, is slated to hold the largest with a share of about 38% by the end of 2037. The region's growing aging population and accompanying demographic shift are likely to drive market demand. The World Health Organization (WHO) projects that by 2050, the share of older adults in Asia will rise to 28.3%.
Postmenopausal osteoporosis is more common than ever before because of the sharp rise in osteoporosis risk that comes with aging. This demographic trend emphasizes the growing incidence of osteoporosis in the senior population, underscoring the need for targeted healthcare measures.
Osteoporosis is becoming more common in the Asia Pacific region as a result of significant dietary and lifestyle changes. Rising urbanization and changing dietary preferences have resulted in a noticeable decline in traditional diets rich in calcium and other minerals that support bone health. Simultaneously, sedentary lifestyles have grown in favor of postmenopausal osteoporosis market.
North America Market Analysis
The postmenopausal osteoporosis market in North America is expected to develop significantly in the upcoming years and is expected to keep the second position. This is due to the region's population's food and lifestyle choices, which have a significant impact on bone health. Adults in North America are showing a worrying trend of insufficient calcium intake, according to a study published in Osteoporosis International.
Unhealthy food choices, such as consuming less dairy and foods high in calcium, can lead to less than ideal bone health. In order to improve bone density and avoid postmenopausal osteoporosis in the North American population, it is imperative that certain lifestyle variables be addressed.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?